BARCELONA, Spain and CAMBRIDGE, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Oryzon Genomics, a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, announced today that Dr. Tamara Maes, Oryzon's Chief Scientific Officer, will present at the Neuroscience R&D Technologies Conference on December 3 - 4, to be held at Hotel Pullman Barcelona Skipper in Barcelona, Spain.
Dr. Maes will be delivering a presentation on the "Role of epigenetics in neurodegenerative disease in general and development of LSD1 inhibitors in particular" on Friday, December 4 at 14:05 pm-14:35 pm. The presentation is part of a broader session that will discuss the recent advancements in next generation neuroscience research.
"LSD1 inhibitors represent a novel approach to potential treatments of neurodegenerative diseases. We are very excited to share our latest findings around LSD1 inhibitors and their therapeutic value. We believe that further studies on LSD1 inhibitors will enable us to develop and advance our candidates for first-in-class therapeutics to treat neurodegenerative disorders," commented Dr. Maes.
The Neuroscience R&D Technologies Conference aims to create a platform that enables stakeholders to discuss, brainstorm and explore solutions to the challenges in the field of neuroscience research. The conference will gather global neuroscience experts to discuss advances in brain imaging, neuroinformatics, animal models, neurogames and neuromodulation, among others. Roche, Eli Lilly, Bristol-Myers Squibb and UCB Biopharma represent a few of the companies that will also be presenting at the conference.
Founded in 2000 in Barcelona, Spain, Oryzon is a privately held, clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with ROCHE. Oryzon's LSD1 program is currently covered by 19 patent families and has rendered one compound in clinical trials and another one is anticipated to enter clinical trials in early 2016. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has also a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com.
CONTACT: US Contact: The Ruth Group Lee Roth/Tram Bui (646) 536-7012/7035 email@example.com firstname.lastname@example.org Spain: ATREVIA Ana Melgar/Patricia Cobo +34 91 564 07 25 email@example.com firstname.lastname@example.org The Company: Ms. Anna K Baran IR Director +44 (0) 752 1083 006 email@example.comSource: Oryzon